Dr. Tulio E. Bertorini, MD

Dr. Bertorini practices at Semmes-Murphey Clinic in Memphis, Tennessee.

Dr. Bertorini's NPI, 1760459168, was assigned on March 3, 2006. Dr. Bertorini holds Tennessee license 10807.

Dr. Bertorini's primary practice is Semmes-Murphey Clinic, at 6325 Humphreys Blvd, Memphis, TN 38120. The practice phone is (901) 522-2655.

Dr. Bertorini's primary practice is Semmes-Murphey Clinic in Memphis, Tennessee. Dr. Bertorini is also affiliated with Methodist University Hospital. The medical group on file is Select Physical Therapy. Dmand AI also links Dr. Bertorini to 4 more hospitals, 4 medical groups, 3 group practices and clinics, 1 home health agency and 1 ambulatory surgery center, each named with a free account. Dr. Bertorini's employer is on file too: a surgery center (asc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bertorini practices, 11 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Bertorini's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Bertorini is licensed in Tennessee.

CMS data shows 45,512 Medicare services from Dr. Bertorini across 28 procedure codes in 2024, for 619 Medicare patients. Medicare paid $1,181,141 for them. Every service was in an office.

CMS counts 619 Medicare patients who saw Dr. Bertorini in 2024. The largest group is 65 to 74, with 256 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.43, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Bertorini's median patient age at 65, with 58% women.

In 2024, Dr. Bertorini wrote 3,701 Medicare Part D claims for 388 patients. 73% of them were for generic drugs. CMS names the drug for 3,390 of them, across 70 drugs with 11 or more claims each, at $8,748,695 in total drug cost. In 2023, CMS named 2,962 claims across 59 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Bertorini for performance year 2024, reported as part of a group. Dr. Bertorini accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bertorini as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 40 papers to Dr. Bertorini, published from 2011 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Amyotrophic Lateral Sclerosis, Muscle Weakness and Creatine Kinase. Dr. Bertorini has published most often in Amyotroph Lateral Scler Frontotemporal Degener. Dr. Bertorini's most frequent co-authors are Richard Stanley Bedlack, MD, PhD, Paul E. Barkhaus, MD and Mark B. Bromberg, MD, PhD.

Dmand AI links Dr. Bertorini to 4 clinical trials. 1 is still active or recruiting. Conditions studied include Cognitive Dysfunction, Miller Fisher Syndrome and Muscular Dystrophy, Duchenne. Open Payments lists research payments to Dr. Bertorini that name 1 trial.

CMS Open Payments shows 1,465 general payments to Dr. Bertorini from 64 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 58% of the total. Alexion Pharmaceuticals, Inc. paid the most, $94,436. It also lists 5 research payments totaling $1,353 in 2019, naming 1 clinical trial.